Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
Novartis has secured exclusive worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager developed by China's Abogen Biosciences. The deal is valued at up to $7.8 billion, with Novartis paying $575 million upfront. The therapy targets B-cell-driven autoimmune diseases. This agreement provides external validation for Abogen's mRNA platform, which previously struggled to find commercial success after its COVID-19 vaccine missed the market window. The partnership expands the RNA therapeutics pipeline for the Swiss pharmaceutical company.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Novartis signed a licensing agreement with Abogen Biosciences valued at up to $7.8 billion.
- ✓ Novartis paid $575 million upfront for the worldwide rights to ABO2203.
- ✓ ABO2203 is an mRNA-encoded T-cell engager targeting autoimmune diseases.
- ✓ The therapy specifically targets B-cell-driven autoimmune diseases.
What changed
New details identify the specific therapy as ABO2203 and confirm a $575 million upfront payment.
Live updates
-
Novartis Pays $575 Million Upfront in $7.8 Billion mRNA Deal with Abogen
Novartis has secured exclusive worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager developed by China's Abogen Biosciences. The deal is valued at up to $7.8 billion, with Novartis paying $575 million upfront. The therapy targets B-cell-driven autoimmune diseases. This agreement provides external validation for Abogen's mRNA platform, which previously struggled to find commercial success after its COVID-19 vaccine missed the market window. The partnership expands the RNA therapeutics pipeline for the Swiss pharmaceutical company.
Why it matters
The deal follows a period of volatility for Novartis, including trial failures that reportedly erased $30 billion in value. It occurs amid geopolitical tensions, though reports suggest the US may allow pharmaceutical partnerships between US and Chinese firms to continue.
What is confirmed
- Novartis signed a licensing agreement with Abogen Biosciences valued at up to $7.8 billion.
- Novartis paid $575 million upfront for the worldwide rights to ABO2203.
- ABO2203 is an mRNA-encoded T-cell engager targeting autoimmune diseases.
- The therapy specifically targets B-cell-driven autoimmune diseases.
Still unconfirmed
- The US is considering allowing US-China pharma deals to continue despite a cautious approach in other sectors.
- Trial failures recently erased $30 billion in value for Novartis.
What to watch next
- Novartis financial results scheduled for late October
- Clinical trial progress for ABO2203
confidence 95%Sources used for this update (19)
- www.marketbeat.com — NVS News Today | Why did Novartis stock go down today?
- www.marketscreener.com — Moderna to join Nasdaq 100, replacing Warner Bros Discovery | MarketScreener
- finance.yahoo.com — Novartis Strengthens RNA Therapeutics Pipeline With $7.8B ...
- www.marketscreener.com — AstraZeneca to Invest Over $1 Billion in Massachusetts | MarketScreener
- ca.marketscreener.com — HEALTH ROUNDS-Experimental approach uses AI to eliminate cold storage for mRNA vaccines | MarketScreener ....
- lifescivoice.com — Abogen Lands $7.8B Novartis Deal for Autoimmune Therapy
- www.manufacturingchemist.com — Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T ...
- www.biospectrumasia.com — Novartis signs licensing deal worth $7.2 B with China's ...
- www.biospace.com — How Abogen went from COVID hype to a $7.8B Novartis deal
- www.europesays.com — Novartis signs $7.8B mRNA deal with Chinese biotech
- globalpolitics.info — Novartis Partners with Abogen on $7.8 Billion Biotech Deal
- www.marketscreener.com — HEALTH ROUNDS-Experimental approach uses AI to eliminate cold storage for mRNA vaccines | MarketScreener
-
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
Novartis has entered a licensing agreement with Chinese biotech firm Abogen Biosciences valued at up to $7.8 billion to develop mRNA-based therapies, focusing on autoimmune diseases. The deal centers on an mRNA-encoded in vivo autoimmune T-cell engager and includes options for additional future therapies. This agreement reflects a broader trend of major pharmaceutical firms increasing their investment and partnership activity within the Chinese biotech market.
Why it matters
The deal highlights Novartis' strategic move to expand its presence in the Chinese biotech market. Major pharmaceutical firms are increasingly investing in and partnering with Chinese biotech companies. The agreement is significant for Novartis as it seeks to develop new therapies for autoimmune diseases.
What is confirmed
- Novartis has entered a licensing agreement with Chinese biotech firm Abogen Biosciences valued at up to $7.8 billion.
- The deal centers on an mRNA-encoded in vivo autoimmune T-cell engager.
- The agreement includes options for additional future therapies from Abogen.
What to watch next
- Progress in development of mRNA-based therapies
- Novartis' future investment in Chinese biotech market
- Regulatory approvals for the deal
confidence 100%Sources used for this update (2)
- www.wallstreet-online.de — Novartis setzt bis zu 7,8 Milliarden Dollar auf Immuntherapie – warum Eli Lilly und Co. die Zelltherapie neu erfinden wollen
- pharma.economictimes.indiatimes.com — Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
-
Novartis signs up to $7.8 billion mRNA deal with China's Abogen
Novartis has entered a licensing agreement with Chinese startup Abogen Biosciences valued at up to $7.8 billion. The deal centers on an mRNA-encoded in vivo autoimmune T-cell engager. Under the terms, Novartis will license the drug candidate and secure options for additional future therapies from the company. This agreement reflects a broader trend of major pharmaceutical firms increasing their investment and partnership activity within the Chinese biotech market.
Why it matters
The partnership focuses on mRNA technology applied to autoimmune treatments. This move aligns with a wider strategic push by global pharmaceutical companies to acquire innovative assets from China.
What is confirmed
- Novartis signed a deal with China's Abogen valued at up to $7.8 billion.
- The agreement involves licensing an mRNA-encoded T-cell engager.
- The drug candidate is an in vivo autoimmune T-cell engager.
What to watch next
- Clinical trial results for the mRNA-encoded T-cell engager
- Novartis exercising options for additional Abogen therapies
confidence 100%Sources used for this update (13)
- WSJ — Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
- Reuters — Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
- CNBC — Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
- fiercebiotech.com — Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
- axios.com — Novartis signs $7.8 billion drug deal with Chinese startup
- BioSpace — Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
- www.devdiscourse.com — Reuters Health News Summary | International
- www.globalbankingandfinance.com — IG Group Cuts 2026 Revenue Outlook on Weaker OTC Trading
- www.globalbankingandfinance.com — Novartis Signs $7.8B mRNA Licensing Deal With China’s Abogen
- www.gdnonline.com — Health: Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
- www.marketscreener.com — Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal -- Update | MarketScreener
- www.marketscreener.com — Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal | MarketScreener
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community